Silver Book Fact
Potential savings from shingles vaccine
Use of the shingles vaccine in immunocompetent adults ages 60 and older could save between $82 and $103 million in healthcare costs associated with the diagnosis and treatment of shingles, post-herpetic neuralgia, and other complications.
Pellesier J, Brisson M, Levin M. Evaluation of the Cost-Effectiveness in the United States of a Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. Vaccine. 2007; 25(49): 8326-37. http://www.ncbi.nlm.nih.gov/pubmed/17980938